. 2020 Oct 2;100(1):11–25. doi: 10.1007/s00277-020-04287-w

Table 4.

Risk factors for clonal evolution and overall survival in female patients affected by polycythemia vera

Event	Female gender
Death	Conflicting data: – No impact as for the IWG-MRT [44] and MIPSS-PV (p = 0.7) models [53] – Lower risk in a retrospective cohort (p = 0.008) [45]
PPV-MF	No difference in the MYSEC as for [91]: – time to progression into PPV-MF (p = 0.49) – the phenotype at PPV-MF diagnosis – mortality (p = 0.45) Lower risk of evolution (Johns Hopkins Hospital) (p = 0.013) [62]
BP	Conflicting data: – Increased risk (ECLAP sub-analysis) (p = 0.04) [43] – Lower rate (Johns Hopkins Hospital) (p < 0.001) [62]

Event

Female gender

Death

Conflicting data:

– No impact as for the IWG-MRT [44] and MIPSS-PV (p = 0.7) models [53]

– Lower risk in a retrospective cohort (p = 0.008) [45]

PPV-MF

No difference in the MYSEC as for [91]:

– time to progression into PPV-MF (p = 0.49)

– the phenotype at PPV-MF diagnosis

– mortality (p = 0.45)

Lower risk of evolution (Johns Hopkins Hospital) (p = 0.013) [62]

Conflicting data:

– Increased risk (ECLAP sub-analysis) (p = 0.04) [43]

– Lower rate (Johns Hopkins Hospital) (p < 0.001) [62]

IWG-MRT, International Working Group for Myeloproliferative Neoplasms Research and Treatment; MIPSS-PV, Mutation-enhanced International Prognostic Scoring System for Polycythemia Vera; MYSEC, Myelofibrosis Secondary project; PPV-MF, post-polycythemia vera myelofibrosis; MYSEC-PM, MYSEC-prognostic model; BP, blast phase; ECLAP, European Collaboration on Low-dose Aspirin in Polycythemia Vera